RCUS
Arcus Biosciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 20 ▼ Arcus Biosciences announced the discontinuation of its Phase 3 STAR-…
- May 11 ▼ 1 insider sell $199.0K at $25.63
- Jun 1 ▼ 1 insider sell $66.0K at $25.77
- Jun 22 to Jun 24 ▼ 3 days of insider sells: $877.5K by 1 insider, avg $27.92
- Jul 9 to Jul 10 ▼ 2 days of insider sells: $2.0M by 1 insider, avg $29.63
- Aug 21 ▼ 1 insider sell $84.8K at $30.00
- Sep 8 Trial readout: Results Pending: Domvanalimab (Phase 3), Completed 11d ago
- Oct 16 William Blair initiates
- Oct 19 Trial readout: Results Pending: Domvanalimab (Phase 2), Completed 32d ago
- Oct 22 ▼ Arcus Biosciences priced a $250M underwritten public offering of 14,…
- Oct 24 Trial readout: Results Pending: Domvanalimab (Phase 3), Completed 57d ago
- Oct 26 Trial readout: Results Pending: Domvanalimab (Phase 2), Completed 49d ago
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $3.3M.
- InstitutionsBULLISH
Q3 2026: 26 added (2 new), 12 trimmed or exited. Largest new: Loomis Sayles & L P $19.1M, Panagora Asset Management $12.1M.
- AnalystsBULLISH
18 of 21 rate it Buy or better.
- Short sellersSTEADY
Short interest +6.6% to 13.18M shares. 3.6 days to cover, ≈9.2% of shares.
- TrendDOWNTREND
25% below its 50-day average. New closing low $16.86 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Invesco Ltd. | ADD | $30.6M |
| MORGAN STANLEY | ADD | $30.1M |
| Aberdeen Group plc | ADD | $27.3M |
| JPMORGAN CHASE & CO | ADD | $19.7M |
| LOOMIS SAYLES & CO L P | NEW | $19.1M |
| UBS Group AG | ADD | $17.2M |
| PANAGORA ASSET MANAGEMENT INC | NEW | $12.1M |
| FIRST TRUST ADVISORS LP | ADD | $11.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 5, 2026 | Truist Securities MAINTAIN | Buy |
| Nov 5, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 21, 2026 | Citigroup MAINTAIN | Buy |
| Oct 21, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 21, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Azoy Alexander Chief Accounting Officer Aug 21, 2026 | EXERCISE | $43.6K |
Azoy Alexander Chief Accounting Officer Aug 21, 2026 | SELL | $84.8K |
Jaen Juan C. President Jul 10, 2026 | SELL | $7.9K |
Jaen Juan C. President Jul 10, 2026 | SELL | $566.4K |
Jaen Juan C. President Jul 9, 2026 | SELL | $1.5M |
Jaen Juan C. President Jun 24, 2026 | SELL | $190.7K |
Jaen Juan C. President Jun 23, 2026 | SELL | $389.5K |
Jaen Juan C. President Jun 23, 2026 | SELL | $47.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.88 | -$1.00–-$0.78 | +3.7% | $6.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 0 bullish · 4 bearish · 1 mixed · 8 neutral- NEUTRAL INST-CLUSTERNov 16, 2026
Institutional activity in Q2 2026 was mixed: 22 buyers added $154.9M in new holdings (led by Fidelity doubling to $124.9M and Goldman Sachs adding to $42.8M), while 11 sellers trimmed $35.9M (led by Marshall Wace cutting $21.3M and BNP Paribas trimming $3.5M). The buying is concentrated among…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL INST-CLUSTERNov 9, 2026
Five institutional investors added $9.8M in RCUS during Q3 2026, led by Aberdeen Group doubling…
The Q3 cluster shows conviction from active asset managers ahead of positive casdatifan data, but the October $250M equity offering at $17.50 (below the Q3 average cost) likely diluted these…
- NEUTRAL 8-KNov 4, 2026
The company highlighted strong clinical data for its lead candidate casdatifan and extended its…
The Q3 results are overshadowed by the casdatifan pipeline catalyst: PEAK-1 enrollment completion and PEAK-20 initiation are near-term milestones. The $288M equity raise provides funding into 2029…
- BEARISH 8-KOct 23, 2026
Arcus Biosciences closed a public offering of 16,428,572 shares of common stock at $17.50 per…
The substantial dilution (~18%) from this overnight offering signals potential cash burn concerns or need to fund clinical development. Monitor upcoming quarterly results for cash runway updates and…
All RCUS filing & press-release reports (13)
- INST-CLUSTER reportNov 16, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportNov 4, 2026
- 8-K reportOct 23, 2026
- 424B5 reportOct 22, 2026
- 424B5 reportOct 21, 2026
- 8-K reportOct 21, 2026
- 8-K reportOct 20, 2026
- 144 reportJul 9, 2026
- DEFA14A reportApr 21, 2026
- 8-K reportApr 20, 2026
- 144 reportApr 8, 2026
- 8-K reportFeb 25, 2026